Rapid Communication
Copyright ©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Nov 7, 2006; 12(41): 6715-6721
Published online Nov 7, 2006. doi: 10.3748/wjg.v12.i41.6715
Table 3 Response to treatment at the end of follow-up n (%)
T-α1 (n = 29)IFN-α (n = 33)HC (after 12 mo of follow-up) (n = 30)
ALT normalization17 (58.6)cf10 (30.3)3 (10)
Negative HBV DNA21 (72.4)df13 (39.4)b2 (6.7)
ALT normal/nagative HBeAg & HBVDNA14 (48.3)f9 (27.3)a1 (3.3)
HBeAg & HBV DNA